CareDx (CDNA)
(Real Time Quote from BATS)
$8.82 USD
-0.01 (-0.11%)
Updated Mar 24, 2023 12:16 PM ET
4-Sell of 5 4
D Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
CDNA 8.82 -0.01(-0.11%)
Will CDNA be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for CDNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CDNA
CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates
Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
CDNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: CareDx (CDNA) Q4 Earnings Expected to Decline
UnitedHealth's (UNH) Optum to Boost Northern Light's Efficiency
HCA Healthcare (HCA) Unit in Talks to Buy Wise Health System
Other News for CDNA
CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association
What You Missed On Wall Street This Morning
What You Missed On Wall Street This Morning
Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations
The American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant Surveillance